TrialNeuro-oncology2020

Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.

Stewart Goldman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.